Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.

British journal of cancer - 1 Dec 2020

Kim Hye Ryun, Kang Han Na, Yun Mi Ran, Ju Kwon Young, Choi Jae Woo, Jung Dong Min, Pyo Kyoung Ho, Hong Min Hee, Ahn Myoung-Ju, Sun Jong-Mu, Kim Han Sang, Kim Jinna, Yoo Jinseon, Kim Kyu Ryung, Koh Yoon Woo, Kim Se Heon, Choi Eun Chang, Yoon Sun Ock, Shim Hyo Sup, Paik Soonmyung, Kim Tae-Min, Cho Byoung Chul

Abstract excerpt

BACKGROUND: Recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is a common cancer with high recurrence and mortality. Current treatments have low response rates (RRs). METHODS: Fifty-three patients with R/M SCCHN received continuous oral buparlisib. In parallel, patient-derived xenografts (PDXs) were established in mice to evaluate resistance mechanisms and efficacy of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Mice, SCID

Share to Morpholines

Share to Neoplasm Transplantation

Share to Progression-Free Survival

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 32963347
DOI: 10.1038/s41416-020-01074-2
PMCID: PMC7722843

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.PMID 32963347Read ↗

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.Semantic proximity Read ↗

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapiesSemantic proximity Read ↗

Establishment of a Large-Scale PDX Library of Head and Neck Cancers for Functional Precision Oncology.Semantic proximity Read ↗

Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)Semantic proximity Read ↗

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular binsSemantic proximity Read ↗

Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer.Semantic proximity Read ↗

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.Semantic proximity Read ↗

Co-expression of NRP1 and p-EGFR in the prognosis of patients with head and neck squamous cell carcinomaSemantic proximity Read ↗

Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCCSemantic proximity Read ↗

Combination of immunotherapy and anti-EGFR agents in immunotherapy refractory head neck cancer recurrent and metastatic head neck squamous cell carcinomaSemantic proximity Read ↗

EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.